Clinical Study

Study Of Amantadine Hcl Extended Release Capsules For The Treatment Of Levodopa Induced Dyskinesia

Posted Date: Apr 15, 2017

  • Investigator: Alberto Espay
  • Co-Investigator: Alberto Espay
  • Specialties: Parkinson's Disease, Neurology, Movement Disorders
  • Type of Study: Drug

Amantadine, in an immediate-release (IR) formulation, is approved by the FDA for the treatment of Parkinson’s disease (PD). Neurologists sometimes also use amantadine to treat levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease, or inv


You Are Being Asked To Participate In This Study Because You Have Parkinson’S Disease And Have Levodopa Induced Dyskinesia. Three Groups Of Lid Patients Are Potentially Eligible To Participate In This Study: • Group 1 Includes Patients Who Are Currently


Adamas Amt-Ads-Pd302, Levodopa Induced Dyskinesia, Amantadine Extended Release, Espay, Parkinson's Disease

For More Information:

Katie Krier
(513) 558-0169

  • Search Clinical Studies

  • Research in the News

    Ride Cincinnati Gives $200,000 in Grants for Breast Cancer Research

    Marlene Harris-Ride Cincinnati has continued its support of UC Cancer Institutescientists with the annual award of five grants to continue promising breastcancer research.